
|Videos|November 12, 2013
The Role of Bevacizumab in Treatment of Metastatic Cervical Cancer
Author(s)Bradley Monk, MD
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.
Advertisement
Clinical Pearls
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.
- The recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer
- Adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%
- Metastatic cervical cancer was previously though to be resistant to chemotherapy
- The FDA will be interested in these data, though it remains to be seen if approval will follow
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















